Verichip Corp - Quarterly Report (10-Q)

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)


þ		QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2007


o		TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 001-33297

VERICHIP CORPORATION

(Exact name of registrant as specified in its charter)


DELAWARE (State or other jurisdiction of incorporation or organization)		06-1637809 (I.R.S. Employer Identification No.)

1690 South Congress Avenue, Suite 200 Delray Beach, Florida 33445 (Address of principal executive offices, including zip code)		(561) 805-8008 (Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of “accelerated filer and large accelerated filer” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer o Accelerated filer o Non-accelerated filer þ

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No þ

The number of shares outstanding of each of the issuer’s classes of common stock as of the close of business on November 2, 2007 is as follows:


Class Common Stock: $0.01 Par Value		Number of Shares 10,114,766

VERICHIP CORPORATION

TABLE OF CONTENTS


PART I — CONDENSED FINANCIAL INFORMATION			1

ITEM 1. CONDENSED FINANCIAL STATEMENTS (Unaudited)			1

Condensed Consolidated Balance Sheets — September 30, 2007 and December 31, 2006			1

Condensed Consolidated Statements Of Operations — Three and Nine Months Ended September 30, 2007 and 2006			2

Condensed Consolidated Statement Of Stockholders’ Equity — Nine Months Ended September 30, 2007			3

Condensed Consolidated Statements Of Cash Flows — Nine months Ended September 30, 2007 and 2006			4

Notes to Unaudited Condensed Consolidated Financial Statements			5

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS			21

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS			23

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK			34

ITEM 4. CONTROLS AND PROCEDURES			34

PART II — OTHER INFORMATION			36

ITEM 1. LEGAL PROCEEDINGS			36

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS			36

ITEM 6. EXHIBITS			37

SIGNATURES			38

Exhibit 10.1
Exhibit 31.1
Exhibit 31.2
Exhibit 32.1

PART I — FINANCIAL INFORMATION

Item 1. Financial Statements.

VERICHIP CORPORATION

Condensed Consolidated Balance Sheets

(In thousands, except par value)


	September 30,			December 31,
	2007			2006
	(unaudited)
Assets
Current Assets:
Cash	$	9,680		$	996
Accounts receivable, net of allowance for doubtful accounts of $144 (2006 - $146)		4,888			4,486
Inventories, net of allowance		2,871			3,698
Prepaid expenses and other current assets		865			567
Deferred tax asset		196			520

Total Current Assets		18,500			10,267
Equipment, net of accumulated depreciation		898			950
Intangible assets, net of accumulated amortization		17,200			18,567
Goodwill		16,025			16,025
Deferred offering costs		—			5,079


	$	52,623		$	50,888


Liabilities and Stockholders’ Equity
Current Liabilities:
Bank indebtedness	$	1,465		$	853
Accounts payable		1,402			3,671
Accrued expenses and other current liabilities		3,899			4,968
Note payable to Parent, current portion		1,601			—

Total Current Liabilities		8,367			9,492
Deferred tax liability		5,092			5,415
Note payable to Parent, less current portion		10,935			13,635

Total Liabilities		24,394			28,542
Commitments and Contingencies

Stockholders’ Equity:
Capital stock:
Preferred stock:
Authorized 5,000 shares of $.001 par value; no shares issued or outstanding		—			—
Common stock:
Authorized 40,000 shares, of $.01 par value; 10,296 and 6,056 shares issued and outstanding at September 30, 2007 and December 31, 2006, respectively		103			61
Treasury stock, at cost; 18 shares		(79	)		—
Additional paid-in capital		54,406			39,371
Accumulated deficit		(26,164	)		(17,049	)
Accumulated other comprehensive loss — foreign currency translation		(37	)		(37	)

Total Stockholders’ Equity		28,229			22,346


	$	52,623		$	50,888

See accompanying notes to condensed consolidated financial statements.

VERICHIP CORPORATION

Condensed Consolidated Statements of Operations

(In thousands, except per share data)

(unaudited)


	For the Three Months						For the Nine Months
	Ended September 30,						Ended September 30,
	2007			2006			2007			2006

Product revenue	$	7,414		$	6,354		$	21,909		$	19,074
Service revenue		502			464			1,570			1,270


Total revenue		7,916			6,818			23,479			20,344

Cost of products		3,071			2,831			9,952			7,843
Cost of services		309			219			898			651


Total cost of products and services		3,380			3,050			10,850			8,494

Gross profit		4,536			3,768			12,629			11,850

Operating expenses:

Selling, general and administrative		6,092			4,348			16,833			12,580
Research and development		1,140			882			3,503			2,700



Total operating expenses		7,232			5,230			20,336			15,280

Operating loss		(2,696	)		(1,462	)		(7,707	)		(3,430	)

Interest income and other expense, net		37			18			120			61
Interest expense		389			219			1,142			501


Total other expense		426			237			1,262			562

Loss before income tax provision (benefit)		(3,122	)		(1,699	)		(8,969	)		(3,992	)
Provision (Benefit) for income taxes		101			(438	)		146			(541	)


Net loss	$	(3,223	)	$	(1,261	)	$	(9,115	)	$	(3,451	)


Net loss per common share — basic and diluted	$	(0.35	)	$	(0.23	)	$	(1.08	)	$	(0.62	)


Weighted average number of shares outstanding — basic and diluted		9,323			5,556			8,479			5,556

See accompanying notes to condensed consolidated financial statements.

VERICHIP CORPORATION

Condensed Consolidated Statement of Stockholders’ Equity

For the Nine Months Ended September 30, 2007

(In thousands)

(Unaudited)


														Accumulated
					Additional									Other			Total
	Common Shares				Paid-in			Treasury			Accumulated			Comprehensive			Stockholders’
	Number		Amount		Capital			Stock			Deficit			Loss			Equity

Balance December 31, 2006		6,056	$	61	$	39,371		$	—		$	(17,049	)	$	(37	)	$	22,346
Net loss		—		—		—			—			(9,115	)		—			(9,115	)
Stock issuance costs		—		—		(5	)		—			—			—			(5	)
Stock based compensation		109		1		2,599			—			—			—			2,600
Issuance of shares from option exercises		536		5		370			—			—			—			375
IBM Warrant exercise		395		4		(4	)		—			—			—			—

Share repurchase		—		—		—			(79	)		—			—			(79	)
Issuance of shares in public offering, net of costs of $8,033		3,100		31		12,076			—			—			—			12,107
Issuance of restricted stock		100		1		(1	)		—			—			—			—


Balance September 30, 2007		10,296	$	103	$	54,406		$	(79	)	$	(26,164	)	$	(37	)	$	28,229

See accompanying notes to condensed consolidated financial statements.

VERICHIP CORPORATION
Condensed Consolidated Statements of Cash Flows
(In thousands)
(unaudited)


	For the Nine Months Ended
	September 30,
	2007			2006

Cash flows from operating activities:
Net loss	$	(9,115	)	$	(3,451	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		1,851			1,791
Stock-based compensation		2,600			154
Accrued interest		1,106			—
Deferred income tax		—			(702	)
(Recovery of) Allowance for doubtful accounts		(2	)		82
Allowance for inventory excess		396			—
Changes in operating assets and liabilities:
Increase in accounts receivable		(400	)		(109	)
Decrease (increase) in inventories		430			(668	)
Increase in prepaid expenses and other current assets		(297	)		(200	)
(Decrease) increase in accounts payable and accrued expenses		(1,606	)		1,258


Net cash used in operating activities		(5,037	)		(1,845	)

Cash flows from investing activities:
Payments for equipment		(432	)		(635	)


Net cash used in investing activities		(432	)		(635	)

Cash flows from financing activities:
Short term borrowings, net		612			986
Proceeds from stock option exercises, net of share repurchase		291			—
Payments to Parent		(3,500	)		—
Borrowings from Parent		1,293			2,066
Initial public offering costs		(2,879	)		(1,133	)
Proceeds from initial public offering, net of underwriter fees		18,336			—


Net cash provided by financing activities		14,153			1,919

Net increase (decrease) in cash		8,684			(561	)
Cash, beginning of period		996			1,440


Cash, end of period	$	9,680		$	879

See accompanying notes to condensed consolidated financial statements.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

1. Business and Basis of Presentation

VeriChip Corporation is a Delaware corporation formed in November 2001. The Company commenced operations in January 2002. On February 14, 2007, the Company completed an initial public offering of its common stock. As of September 30, 2007, Applied Digital Solutions, Inc., Applied Digital, or parent, owned 52.1% of the Company’s common stock.

The accompanying unaudited condensed consolidated financial statements of VeriChip Corporation and its subsidiaries (the “Company,” “Registrant,” “us,” “we,” or “our”) as of September 30, 2007 and December 31, 2006 (the December 31, 2006 financial information included in this report has been extracted from our audited financial statements included in our 2006 Annual Report on Form 10-K), and for the three and nine months ended September 30, 2007 and 2006 have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S.”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X under the Securities Exchange Act of 1934. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the U.S. for complete financial statements. In the opinion of our management, all adjustments (including normal recurring adjustments) considered necessary to present fairly the unaudited condensed consolidated financial statements have been made.

The preparation of financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of sales and expenses during the reporting period. Actual results could differ from those estimates. Included in these estimates are assumptions about allowances for excess inventory, warranty reserves, bad debt reserves, lives of long lived assets, lives of intangible assets, assumptions used in Black-Scholes valuation models, estimates of the fair value of acquired assets and assumed liabilities, the determination of whether any impairment is to be recognized on goodwill or intangibles, among others.

The unaudited condensed consolidated statements of operations for the three and nine months ended September 30, 2007 and 2006 are not necessarily indicative of the results that may be expected for the entire year. These statements should be read in conjunction with the consolidated financial statements and related notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2006.

The Company develops, markets and sells radio frequency identification, frequently referred to as RFID, systems used for the identification, location and protection of people and assets in the healthcare market. The Company’s healthcare security systems utilize external, active RFID tags to locate and protect people and assets. The Company’s VeriMed system uses the implantable microchip, a human-implantable passive RFID microchip that is used in patient identification for access to personal health records. Each implantable microchip contains a unique verification number that is read when it is scanned by the Company’s scanner. In October 2004, the U.S. Food and Drug Administration, or FDA, cleared the Company’s VeriMed system for use in medical applications in the United States.

The Company purchases the implantable microchip from Digital Angel Corporation, or Digital Angel, a majority-owned subsidiary of Applied Digital, under the terms of an amended and restated supply agreement. The supply agreement is discussed in Note 11, “Related Party Transactions.” Digital Angel, in turn, obtains the implantable microchip, a component of the VeriChip, from a subsidiary of Raytheon Company, under a separate supply agreement. The technology underlying these systems is covered, in part, by U.S. Patent No. 5,211,129 “Syringe-Implantable Identification Transponders,” which the Company refers to as the ‘129 patent. In 1994, Destron/IDI, Inc., a predecessor company to Digital Angel, granted a co-exclusive license under this patent, other than for certain specified fields of use retained by the predecessor company, to Hughes Aircraft Company, or Hughes, and its then wholly-owned subsidiary, Hughes Identification Devices, Inc., or HID. The specified fields of use retained by the predecessor company do not include human identification or security applications. The rights licensed to Hughes and HID were freely assignable, and the Company does not know which party or parties currently have these rights or whether these rights have been assigned, conveyed or transferred to any third party. Digital Angel sources the implantable microchip indirectly from a subsidiary of Raytheon Company, with which Hughes, then known as HE Holdings, Inc., was merged in 1997. However, the Company has no documentation that establishes its right to use the patented technology for human identification or security applications. Hughes, HID, any of their respective successors in interest, or any party to whom any of the foregoing parties may have assigned its rights under the 1994 license agreement may commence a claim against the Company asserting that the Company is violating its rights.

In October 2007, Digital Angel and the successor to HID executed a cross-license which includes Digital Angel obtaining a royalty free non-exclusive license to HID’s rights to the implantable human applications of the ‘129 patent, for which it purports certain ownership rights to. Digital Angel has, in turn, sublicensed those rights to VeriChip. (See Note 9 “Unasserted Claim — Potential Intellectual Property Conflict” and Note 11 “Related Party Transactions”).

Initial Public Offering and Underwriting Agreement

On February 14, 2007, the Company completed an initial public offering of its common stock. In connection with the initial public offering, 3,100,000 shares of its common stock were sold. The Company, Applied Digital and Merriman Curhan Ford & Co., as representative of the several underwriters, entered into a underwriting agreement. The initial public offering price was $6.50 per share and the underwriting discounts and commissions were $0.455 per share.

The underwriting agreement required the Company to reimburse the underwriters for their expenses on a non-accountable basis in the amount equal to 1.3% of the aggregate public offering price. In addition, the Company reimbursed the underwriters $150,000 of their legal fees incurred in connection with the offering.

A reconciliation of net proceeds from the initial public offering is provided as follows:


	Amount

Gross proceeds from public offering	$	20,150

Less fees and offering costs:
Underwriter discounts and fees		1,814
Offering costs paid prior to 2007		3,350
Offering costs paid in 2007		2,879


Net proceeds from public offering	$	12,107

In the nine months ended September 30, 2006, the Company paid $1.1 million in initial public offering costs.

Registration Rights Agreement

On August 31, 2007, the Company entered into a Registration Rights Agreement with Kallina Corporation. The Agreement was entered into in connection with the execution of a Securities Purchase Agreement between Applied Digital and Kallina Corporation under which Applied Digital transferred to Kallina Corporation 200,000 shares of Company common stock that Applied Digital owned. Under the agreement, the Company will register the 200,000 shares for resale by Kallina Corporation. Applied Digital has agreed to use its best efforts to enter into a subordination agreement with a potential third party lender to the Company and to reimburse the Company for all out of pocket expenses, including legal, accounting, filing, and printing expenses, related to the agreement.

Stock Repurchase Program

On September 20, 2007, the Company’s board of directors approved a stock repurchase program, authorizing the purchase of $1.5 million of its common stock over four months. As of September 30, 2007, 18,000 shares were repurchased at a cost of approximately $79,000. From October 1 to November 7, 2007, the Company repurchased 0.2 million shares at a cost of $0.7 million. For more information, see Note 5 and Item 2 — Unregistered Sales of Equity Securities and Use of Proceeds.

Stock-Based Compensation

Effective January 1, 2006, the Company adopted Financial Accounting Standards Board (“FASB”) SFAS No. 123 (revised 2004), Share Based Payment , or FAS 123R using the modified prospective transition method. Under this method, stock-based compensation expense is recognized using the fair-value based method for all awards granted on or after the date of adoption. Compensation expense for new awards granted after January 1, 2006 is recognized over the requisite service period based on the grant-date fair value of those options. Prior to adoption, the Company used the intrinsic value method under Accounting Principles Board (“APB”) 25, and related interpretations and provided the disclosure-only provisions of FAS 123. Under the intrinsic value method, no stock-based compensation had been recognized in our consolidated statement of operations for options granted to the Company’s employees and directors because the exercise price of such stock options equaled or exceeded the fair market value of the underlying stock on the dates of grant.

We recorded compensation expense, related to stock options, of approximately $0.1 million and $0.3 million for the three and nine months ended September 30, 2007, respectively, and nil and approximately $31,000 in the three and nine months ended September 30, 2006, respectively.

In December 2006, the Company issued 0.5 million shares of its restricted common stock to Scott R. Silverman, its chairman and chief executive officer, which shares are subject to forfeiture in the event that Mr. Silverman terminates his employment or the Company terminates his employment for cause on or before December 31, 2008. The Company determined the value of the stock to be $4.5 million based on the estimated value of its common stock of $9.00 per share on the date of grant. The value of the restricted stock is being amortized as compensation expense over the vesting period. The Company recorded compensation expense of approximately $0.5 million and $1.6 million in the three and nine months ended September 30, 2007 associated with the restricted stock.

In March 2007, the Company issued 0.1 million shares of its restricted common stock to two officers, which shares will vest on March 2, 2009. The Company determined the value of the stock to be $0.6 million based on the value of its common stock of $5.75 per share on the date of grant. The value of the restricted stock is being amortized as compensation expense over the vesting period. The Company recorded compensation expense of approximately $0.1 million and $0.2 million in the three and nine months ended September 30, 2007 associated with this restricted stock.

In August 2007, the Company entered into a consulting agreement with an individual, who was the former Chief Executive Officer of Digital Angel, with respect to identifying, contacting and introducing strategic partners to the Company, identifying potential merger and/or acquisition opportunities for the Company and participating with the Company inits efforts to develop certain products related to an implantable glucose bio-sensor microchip. Under the consulting agreement, the Company issued 107 thousand common shares, which resulted in an equity based compensation charge of $0.6 million during the three months ended September 30, 2007.

Stock-based compensation expense is reflected in the unaudited condensed consolidated statement of operations in selling, general and administrative expense.

The Company’s computation of expected life is determined based on the simplified method. The interest rate is based on the U.S. Treasury Yield curve in effect at the time of grant. Prior to its initial public offering, the Company’s computation of expected volatility was based on the historical volatility of Applied Digital’s common stock. Effective February 9, 2007, the Company’s computation of expected volatility is based on the historical volatility of the Company’s comparable companies’ average historical volatility.

2. Principles of Consolidation

The financial statements include the accounts of the Company and its wholly-owned Canadian subsidiaries, VeriChip Holdings Inc., or VHI, and Xmark Corporation, or Xmark. All significant inter-company transactions and balances have been eliminated in consolidation.

3. Inventories


	September 30,			December 31,
	2007			2006
Raw materials	$	1,395		$	1,489
Work in process		590			1,255
Finished goods		1,448			1,119

		3,433			3,863
Allowance for excess and obsolescence		(562	)		(165	)


	$	2,871		$	3,698

4. Financing Agreements:

VHI is a party to a credit agreement with the Royal Bank of Canada. The credit facility provides for borrowings up to CDN $1.5 million, or approximately U.S. $1.5 million at September 30, 2007. Approximately USD $1.5 million was outstanding under the credit facility as of September 30, 2007. The annual interest rate on the facility is the Royal Bank of Canada prime rate of interest plus 1%. The borrowing limit is up to 85% of eligible accounts receivable and up to 25% of eligible inventory. Under the terms of the agreement, the Company must comply with certain reporting covenants and requirements. The loan is collateralized by all of the assets of VHI. At September 30, 2007, VHI had aggregate net assets of approximately USD $40.3 million.

The Company entered into a loan agreement with Applied Digital, which has resulted in an amount due to Applied Digital totaling $12.5 million at September 30, 2007. The loan agreement is more fully described in Note 11, “Related Party Transactions.”

5. Stockholders’ Equity

On February 14, 2007, the Company completed an initial public offering of its common stock. In connection with its initial public offering, the Company sold 3,100,000 shares of its common stock at a price of $6.50 per share. As a result, as of September 30, 2007, Applied Digital owned 52.1% of the Company’s common stock.

On September 20, 2007, the Company’s board of directors approved a stock repurchase program authorizing the purchase of $1.5 million of its common stock over four months. As of September 30, 2007, 18,000 shares were repurchased at a cost of approximately $79,000.

Stock Option Plans

In April 2002, the Company’s board of directors approved the VeriChip Corporation 2002 Flexible Stock Plan, or the VeriChip 2002 Plan. Under the VeriChip 2002 Plan, the number of shares for which options, SARs or performance shares, may be granted is approximately 2.0 million. As of September 30, 2007 approximately 1.9 million options and restricted shares, net of forfeitures, have been granted to directors, officers and employees under the VeriChip 2002 Plan, and 1.6 million of the options or shares granted were outstanding as of September 30, 2007. Approximately 1.4 million options are fully vested and expire up to nine years from the vesting date and 0.2 million options vest ratably over three years. As of September 30, 2007, no SARs have been granted and 22,000 shares may still be granted under the VeriChip 2002 Plan.

On April 27, 2005, Applied Digital’s board of directors approved the VeriChip Corporation 2005 Flexible Stock Plan, or the VeriChip 2005 Plan. Under the VeriChip 2005 Plan, the number of shares for which options, SARs or performance shares may be granted is approximately 0.3 million. As of September 30, 2007, approximately 0.3 million options have been granted under the VeriChip 2005 Plan. None of the options are fully vested and expire up to nine years from the vesting date and vest ratably over three years. As of September 30, 2007, no SARs have been granted and 832 shares may still be granted under the VeriChip 2005 Plan.

On June 17, 2007, the Company adopted the VeriChip 2007 Stock Incentive Plan, or the VeriChip 2007 Plan. Under the VeriChip 2007 Plan, the number of shares for which options, SARs or performance shares may be granted is 1.0 million. As of September 30, 2007, approximately 0.1 million options and shares have been granted under the VeriChip 2007 Plan. As of September 30, 2007, no SARs have been granted and 0.9 million shares may still be granted under the VeriChip 2007 Plan.

In addition, as of September 30, 2007, options exercisable for approximately 0.4 million shares of the Company’s common stock have been granted outside of the Company’s plans, and 0.3 million of the options or shares granted were outstanding as of September 30, 2007. These options were granted at exercise prices ranging from $0.23 to $8.55 per share, are fully vested and are exercisable for a period of up to seven years.

In the nine months ended September 30, 2007, 0.1 million, 0.2 million, and 0.1 million options and shares have been granted under the VeriChip 2002 Plan, the VeriChip 2005 Plan, and the VeriChip 2007 Plan, respectively. In the nine months ended September 30, 2006, 50,000 and 2,012 options were granted under the 2002 Plan and outside of the Company’s plans, respectively.

A summary of option activity under our option plans as of September 30, 2007, and changes during the nine months then ended is presented below (in thousands, except per share amounts):


				Weighted
				Average
				Exercise
	Number of			Price Per
	Options			Share
Outstanding on January 1, 2007		2,099		$	2.10
Granted ⁽¹⁾		422			5.88
Exercised ⁽²⁾		(536	)		0.70
Forfeited		(22	)		5.75


Outstanding on September 30, 2007		1,963			3.26


Exercisable on September 30, 2007 ⁽³⁾		1,530			2.42


Options available on September 30, 2007 for future grants		894


(1)		The total compensation expense associated with the options granted in the three and nine months ended September 30, 2007 was approximately $0.1 million and $0.2 million, respectively. The remaining amount of the compensation expense to be recorded over the remaining vesting period of the options is approximately $1.0 million.

(2)		In the three and nine months ended September 30, 2007, 44 and 536 options were exercised under the VeriChip 2002 Plan and outside the Company’s plan, respectively. No options were exercised in the three and nine months ended September 30, 2006. The intrinsic value of a stock option is the amount by which the fair value of the underlying stock exceeds the exercise price of the option. Total intrinsic values of options exercised for the VeriChip 2002 Plan and outside of the Company’s plan were $2.5 million and $0.2 million for the nine months ended September 30, 2007.


(3)		The intrinsic value of a stock option is the amount by which the fair value of the underlying stock exceeds the exercise price of the option. Based upon the Company’s closing price on the NASDAQ, the fair value of the underlying stock was $4.02 at September 30, 2007. As of September 30, 2007, the aggregate intrinsic value of all options outstanding was $1.5 million.

The following table summarizes information about stock options at September 30, 2007 (number amounts, except weighted-average amounts):


							Exercisable Stock
	Outstanding Stock Options						Options
			Weighted-		Weighted-				Weighted-
			Average		Average				Average
			Remaining		Exercise				Exercise
Range of			Contractual		Price Per				Price Per
Exercise Prices	Number		Life (years)		Share		Number		Share
$0.0000 to $2.0250		1,087		2.7	$	0.47		1,087	$	0.47
$4.0501 to $6.0750		436		9.1		5.65		67		5.12
$6.0751 to $8.1000		328		6.2		7.09		298		7.04
$8.1001 to $10.1250		106		7.2		9.23		72		8.88
$18.2251 to $20.2500		6		5.3		20.25		6		20.25


		1,963		5.0	$	3.26		1,530	$	2.42

The weighted average per share fair value of grants made in the nine months ended September 30, 2007 and 2006 for the Company’s incentive plans was $2.98 and $5.97, respectively.

The Black-Scholes model, which the Company used to determine compensation expense, required the Company to make several key judgments including:

•		the estimated value of the Company’s common stock;

•		the expected life of issued stock options;

•		the expected volatility of the Company’s stock price;

•		the expected dividend yield to be realized over the life of the stock options; and

•		the risk-free interest rate over the expected life of the stock options.

The Company prepared these estimates based upon its historical experience, the stock price volatility of comparable publicly-traded companies, including Applied Digital, and its best estimation of future conditions.

The fair values of the options granted were estimated on the grant date using the Black-Scholes valuation model based on the following weighted-average assumptions:


	2007			2006

Expected dividend yield		—			—
Expected stock price volatility		50	%		60	%
Risk-free interest rate		4.51	%		4.29	%
Expected term (in years)		6.0			5.0

6. Loss per Common Share

A reconciliation of the numerator and denominator of basic and diluted loss per common share is provided as follows (in thousands, except per share data):


	For the Three Months						For the Nine Months
	Ended						Ended
	September 30,						September 30,
	2007			2006			2007			2006

Numerator for basic and diluted loss per share:
Net loss	$	(3,223	)	$	(1,261	)	$	(9,115	)	$	(3,451	)


Denominator for basic and diluted loss per share:
Weighted average shares outstanding basic and diluted		9,323			5,556			8,479			5,556


Basic and diluted loss per share	$	(0.35	)	$	(0.23	)	$	(1.08	)	$	(0.62	)

The following stock options and warrants outstanding as of September 30, 2007 and 2006 were not included in the computation of dilutive loss per share because the net effect would have been anti-dilutive:


	For the Nine Months
	Ended
	September 30,
	2007		2006

Stock options		1,963		2,099
Warrants		33		444
Restricted common stock		600		—


		2,596		2,493

7. Segmented information:

In early 2007, the Company realigned its business into three business segments: healthcare security, implantable, and industrial. This change was made to align the Company’s financial reporting with its new operational management structure. All segment information in this Quarterly Report on Form 10-Q has been reclassified to reflect the segment realignment.

Healthcare Security

Utilizing RFID technology, the Company’s Healthcare Security segment currently engages in marketing, selling and developing the following products:

•		infant protection systems used in hospital maternity wards and birthing centers to prevent infant abduction and mother-baby mismatching;

•		wander prevention systems used by long-term care facilities to locate and protect their residents; and

•		asset/staff location and identification systems used by hospitals and other healthcare facilities to identify, locate and protect medical staff, patients, visitors and medical equipment.

Implantable

The Company’s Implantable segment includes its VeriMed system using the implantable microchip, a human-implantable RFID microchip that is used in patient identification for access to personal health records. Each implantable microchip contains a unique verification number that is read when it is scanned by the Company’s scanner. In October 2004, the FDA cleared the Company’s VeriMed system for use in medical applications in the United States.

Industrial

The Company’s Industrial segment engages in marketing, selling and developing the following products:

•		vibration monitoring instruments used by engineering, construction and mining professionals to monitor the effects of human induced vibrations, such as blasting activity; and

•		asset management systems that industrial companies use to manage and track their mobile equipment and tools.

The following is the selected segment data as of and for the three months ended September 30:


	Healthcare
2007	Security		Implantable			Industrial		Corporate			Total

Product revenue	$	5,715	$	53		$	1,646	$	—		$	7,414
Services revenue		158		—			344		—			502


	$	5,873	$	53		$	1,990	$	—		$	7,916


Operating (loss) income		750		(1,437	)		112		(2,121	)		(2,696	)
Depreciation and amortization		526		8			63		8			605
Equity based compensation		—		130			—		1,168			1,298
Interest income and other expense, net		86		—			29		(78	)		37
Interest expense		20		—			—		369			389
Income (loss) before provision (benefit) for income taxes	$	644	$	(1,437	)	$	83	$	(2,412	)	$	(3,122	)


Segmented assets	$	35,674	$	1,015		$	8,958	$	6,976		$	52,623


	Healthcare
2006	Security		Implantable			Industrial		Corporate			Total

Product revenue	$	4,934	$	14		$	1,406	$	—		$	6,354
Services revenue		147		—			317		—			464


	$	5,081	$	14		$	1,723	$	—		$	6,818


Operating income (loss)		115		(1,038	)		46		(585	)		(1,462	)
Depreciation and amortization		429		12			166		12			619
Equity based compensation		—		—			—		124			124
Interest income and other expense, net		14		—			4		—			18
Interest expense		62		—			—		157			219
Loss (income) before provision (benefit) for income taxes		39		(1,038	)		42		(742	)		(1,699	)


Segmented assets	$	34,382	$	1,113		$	10,972	$	3,272		$	49,739

The following is the selected segment data as of and for the nine months ended September 30:


	Healthcare
2007	Security		Implantable			Industrial		Corporate			Total

Product revenue	$	16,622	$	54		$	5,233	$	—		$	21,909
Services revenue		424		—			1,146		—			1,570


	$	17,046	$	54		$	6,379	$	—		$	23,479


Operating (loss) income		987		(3,922	)		539		(5,311	)		(7,707	)
Depreciation and amortization		1,400		28			396		28			1,852
Equity based compensation		—		260			—		2,340			2,600
Interest income and other expense, net		270		—			90		(240	)		120
Interest expense		38		—			—		1,104			1,142
(Loss) income before provision (benefit) for income taxes	$	679	$	(3,922	)	$	449	$	(6,175	)	$	(8,969	)


Segmented assets	$	35,674	$	1,015		$	8,958	$	6,976		$	52,623


	Healthcare
2006	Security		Implantable			Industrial			Corporate			Total

Product revenue	$	14,683	$	114		$	4,277		$	—		$	19,074
Services revenue		282		—			988			—			1,270


	$	14,965	$	114		$	5,265		$	—		$	20,344


Operating income (loss)		389		(2,657	)		708			(1,870	)		(3,430	)
Depreciation and amortization		1,254		31			475			31			1,790
Equity based compensation		—		—			—			124			124
Interest income and other expense, net		69		—			(8	)		—			61
Interest expense		66		—			—			435			501
Income (loss) before provision (benefit) for income taxes	$	254	$	(2,657	)	$	716		$	(2,305	)	$	(3,992	)


Segmented assets	$	34,382	$	1,113		$	10,972		$	3,272		$	49,739

8. Income Taxes

We had an effective tax rate of (1.6)% and (15.7)% for the nine months ended September 30, 2007 and 2006, respectively, related to our Canadian-based business. We incurred consolidated losses before taxes for the nine months ended September 30, 2007 and 2006. However, we have not recorded a tax benefit for the resulting U.S. net operating loss carryforwards, as we have determined that a valuation allowance against our net U.S. deferred tax assets was appropriate based primarily on our historical operating results.

FASB Interpretation No. 48, Accounting for Uncertainty in Income Taxes (“FIN 48”), was issued to clarify the requirements of Statement of Financial Accounting Standards No. 109, Accounting for Income Taxes , relating to the recognition of income tax benefits.

FIN 48 provides a two-step approach to recognizing and measuring tax benefits when the benefits’ realization is uncertain. The first step is to determine whether the benefit is to be recognized, and the second step is to determine the amount to be recognized:

• Income tax benefits should be recognized when, based on the technical merits of a tax position, the entity believes that if a dispute arose with the taxing authority and were taken to a court of last resort, it is more likely than not (i.e., a probability of greater than 50 percent) that the tax position would be sustained as filed; and

• If a position is determined to be more likely than not of being sustained, the reporting enterprise should recognize the largest amount of tax benefit that is greater than 50 percent likely of being realized upon ultimate settlement with the taxing authority.

Effective January 1, 2007, the Company adopted FIN 48. The implementation of FIN 48 did not result in any adjustment to the Company’s beginning tax positions. The Company continues to fully recognize its tax benefits which are offset by a valuation allowance to the extent that it is more likely than not that the deferred tax assets will not be realized.

The Company files federal and provincial income tax returns in Canada and files federal and state income tax returns in the U.S. The Company is generally no longer subject to federal and provincial income tax examinations by Canadian tax authorities for years before 2001 and to federal and state income tax examinations by U.S. tax authorities for years before 2003. Management does not anticipate that adjustments, if any, which may be proposed by the Canadian Revenue Agency would result in a material change to its financial position.

The Company recognizes any interest accrued related to unrecognized tax benefits or exposures in interest expense and penalties in operating expenses. During the nine months ended September 30, 2007 and 2006, there was no such interest or penalty.

9. Unasserted Claim—Potential Intellectual Property Conflict

Hughes, HID, any of their respective successors in interest, or any party to whom any of the foregoing parties may have assigned its rights under the 1994 license agreement (see Note 1) may commence a claim against the Company asserting that the Company is violating its rights. If such a claim is successful, sales of the Company’s implantable microchip could be enjoined and the Company could be required to cease its efforts to create a market for it implantable microchip until the patent expires in April 2008. In addition, the Company could be required to pay damages, which may be substantial. Management is not aware of any claims asserting that the Company is violating the intellectual property rights owned by another company or person.

If the Company or Digital Angel is denied use of the patented technology in applications involving the identification of human beings, the Company will not be able to purchase or sell any of its products that incorporate the implantable microchip before the patent expires. The Company may be required to pay royalties and other damages to third parties on products it has already purchased or will purchase from Digital Angel.

The Company has been publicly marketing and selling the implantable microchip for human identification and security applications for approximately five years. The Company’s supply and development agreement with Digital Angel contains an indemnification provision. To the extent that such an infringement claim is made, the Company believes it is entitled to indemnification pursuant to the supply and development agreement with Digital Angel.

Under the circumstances, the accompanying financial statements make no provision with respect to the unasserted claim described above.

10. Legal proceedings

The Company is engaged in certain legal actions and management believes that the ultimate outcome of these actions will not have a material adverse effect on the Company’s operating results, liquidity or financial position.

Metro Risk

On January 10, 2005, the Company commenced an action in the Circuit Court for Palm Beach County, Florida, against Metro Risk Management Group, LLC, or Metro Risk. In this suit, the Company has claimed that Metro Risk breached the parties’ three international distribution agreements by failing to meet required minimum purchase obligations. On July 1, 2005, Metro Risk asserted a counterclaim against the Company for breach of contract and fraud in the inducement. Specifically, in its claim for breach of contract, Metro Risk alleged that the Company breached the exclusivity provision of the parties’ distribution agreements by later signing a different distribution agreement with a large distributor of medical supplies. Metro Risk asserted that the distribution agreement with this other distributor included areas in Europe. Moreover, regarding its claim for fraud in the inducement, Metro Risk alleged that the Company fraudulently induced Metro Risk into signing the distribution agreements by promising millions of dollars in profits and then later signing a different distribution agreement with a large distributor of medical supplies. By virtue of its counterclaim, Metro Risk seeks reliance damages in the amount of $155,000, which represents the amount of money advanced by Metro Risk for the project, lost profits, and attorneys’ fees. Given the early stage of the matter and because discovery has recently begun, counsel is currently unable to assess the Company’s risk.

Stock Option Plans

The Company has received demand letters from attorneys for several former employees and/or consultants of the Company and Applied Digital, asserting claims related to stock options to acquire approximately 540 thousand shares of the Company’s common stock that management believes that such employees and/or consultants had forfeited when they ceased their employment or relationship with the Company and/or Applied Digital. The Company believes that all of these potential claims are without merit and intends to vigorously defend them in the event the claims are asserted or litigated.

The Company is a party to various legal actions, as either plaintiff or defendant, including the matters identified above, arising in the ordinary course of business, none of which management believes will have a material adverse effect on our business, financial condition or results of operations.

11. Related Party Transactions

Transition Services Agreement with Applied Digital

During the nine months ended September 30, 2007, Applied Digital provided certain general and administrative services to the Company including, accounting, finance, payroll and legal services, telephone, rent and other miscellaneous items. The costs of these services, which are included in the Company’s statement of operations in selling, general and administrative expense, were determined based on the Company’s use of such services. In determining the Company’s estimated use, Applied Digital and the Company determined the actual cost incurred for each of the services that Applied Digital provided to the Company and determined the allocation of each cost that was attributable to the Company’s operations.

The services provided and the basis of allocation was as follows:

•		Accounting, finance and payroll services — these costs were allocated based upon a percentage of the total labor dollars incurred by Applied Digital’s accounting, finance and payroll staff in performing such functions for the Company;

•		Legal services — the costs were allocated based upon a percentage of Applied Digital’s general counsel’s salary and benefits based upon the estimated time spent by its general counsel on the Company’s legal issues;

•		Accounting fees — these costs were allocated based upon actual total fees charged by third party accountants, considering the amount of such accounting fees that the Company would have incurred if it was a stand-alone entity;

•		Rent — the cost was determined based upon the amount of office space square footage that the Company’s employees used; and

•		Telephone, office supplies and other costs — these costs were allocated based upon a percentage of the services or supplies that the Company was deemed to incur.

On December 25, 2005, the Company entered into a transition services agreement with Applied Digital under which Applied Digital agreed to provide the Company with certain administrative transition services. On December 21, 2006, the Company and Applied Digital entered into an amended and restated transition services agreement, which became effective on February 14, 2007, the date of completion of the Company’s initial public offering of the Company’s common stock. Prior to that time, the initial transition services agreement remained in effect. The term of the amended and restated agreement will continue until such time as the Company requests Applied Digital to cease performing transition services, provided that Applied Digital is not obligated to continue to provide the transition services for more than twenty-four months following the effective date. Except for any request by the Company that Applied Digital cease to perform transition services, subject to certain notice provisions, the agreement may not be terminated by either party except in the event of a material default in Applied Digital’s delivery of the transition services or in the Company’s payment for those services. The services to be provided by Applied Digital under the amended and restated transition services agreement are the same as those provided under the initial agreement. The estimated monthly charge for the fixed costs allocable to these services was increased to approximately $72,000 per month, primarily as the result of an increased allocation for office space. Effective April 1, 2007, the estimated monthly charge for the fixed costs allocable to these services was reduced to $40,000 per month, primarily as a result of a reduction in allocable accounting fees and accounting and legal services.

The terms of the transition services agreement and the amendment and restatement of the agreement were negotiated between certain of the Company’s executive officers and certain executive officers of Applied Digital. The Company’s and Applied Digital’s executive officers were independent of one another and the terms of the agreement were based upon historical amounts incurred by Applied Digital for payment of such services to third parties. Accordingly, the Company believes that it negotiated the best terms and conditions under the circumstances, however, these costs are not necessarily indicative of the costs which the Company would have incurred as an independent stand-alone entity.

Management believes that the fees charged for these services are reasonable and consistent with what the expenses would have been on a stand-alone basis. The costs of these services to the Company were $0.1 million and $0.4 million for the three and nine months ended September 30, 2007, respectively, and $0.2 million and $0.5 million for the three and nine months ended September 30, 2006, respectively.

Loan Agreement with Applied Digital

Applied Digital funded and financed the Company’s operations from its inception, through its initial public offering which resulted in an amount due to Applied Digital totaling $13.6 million at December 31, 2006. On December 27, 2005, the Company and Applied Digital converted the amounts due to Applied Digital, including interest accrued, into a revolving line of credit under the terms of a loan agreement, security agreement and a revolving line of credit note.

On October 6, 2006, the Company entered into an amendment to the loan agreement, which increased the principal amount available thereunder to $13.0 million, and the Company borrowed an additional $2.0 million under the agreement to make the second purchase price payment with respect to its acquisition of Instantel. In connection with that amendment, the interest rate was also changed to a fixed rate of 12% per annum. Previously, the Company’s indebtedness to Applied Digital bore interest at the prevailing prime rate of interest as published from time to time by The Wall Street Journal . That amendment further provided that the loan matured in July 2008, but could be extended at the option of Applied Digital through December 27, 2010.

On January 19, 2007, February 8, 2007 and February 13, 2007, the Company entered into further amendments to the loan documents, which increased the maximum principal amount of indebtedness that the Company may incur to $14.5 million. A portion of this increase was used to cover approximately $0.7 million of intercompany advances made to the Company by Applied Digital during the first week of January 2007. Upon the consummation of the Company’s initial public offering in February 2007, the loan ceased to be a revolving line of credit, and the Company has no ability to incur additional indebtedness under the loan documents. The interest continues to accrue on the outstanding indebtedness at a rate of 12% per annum. On February 14, 2007, the closing date of the Company’s initial public offering, the Company was indebted to Applied Digital in the amount of $15.2 million, including $1.0 million of accrued interest and, in accordance with the terms of the loan agreement as most recently amended on February 13, 2007, the Company used $3.5 million of the net proceeds of its initial public offering to repay a portion of its indebtedness to Applied Digital upon consummation of its initial public offering. The Company is not obligated to repay an additional amount of its indebtedness until January 1, 2008. Effective with the payment of the $3.5 million, all interest which accrues on the loan as of the last day of each month, commencing with February 2007, shall be added to the principal amount. Commencing January 1, 2008 through January 1, 2010, the Company is obligated to repay $300,000 on the first day of each month. A final balloon payment equal to the outstanding principal amount then due under the loan plus all accrued and unpaid interest will be due and payable on February 1, 2010.

The loan is collateralized by interests in all property and assets of the Company, including the stock of the Company’s subsidiaries, but is not secured by any of the property or assets of the Company’s subsidiaries. As of September 30, 2007, the amount due on the loan was $12.5 million.

Interest expense incurred under the loan for the three and nine months ended September 30, 2007 was $0.4 million and $1.1 million, respectively, and $0.2 million and $0.4 million for the three and nine months ended September 30, 2006, respectively. The previously floating rate of interest negotiated between the parties was based upon the rate that Applied Digital has historically charged to its wholly-owned subsidiaries. On October 6, 2006, the interest rate was modified as discussed above. The modified interest rate was negotiated between the parties and represents the current rate that Applied Digital is incurring on debt owed to its lender. Depending upon the Company’s future operating performance, this interest rate may not be comparable to the terms that the Company could obtain from independent third parties.

Supply Agreement with Digital Angel

The Company and Digital Angel executed a supply and development agreement dated March 4, 2002 as amended and restated on December 27, 2005 and as amended on May 9, 2007, or the supply and development agreement. Under this agreement, Digital Angel is the Company’s sole supplier of human-implantable microchips and the Company has the exclusive license to the technology related to human-implantable microchips.

The Company’s purchases of product under the supply and development agreement were approximately nil and $0.2 million in the nine months ended September 30, 2007 and 2006, respectively. Under the terms of the May 9, 2007 amendment, the term of the agreement was extended from March 2013 to March 2014. Also, under the May 9, 2007 amendment, the annual minimum purchase requirements were each extended one year and, accordingly, there is no minimum purchase requirement in 2007. The approximately $0.9 million originally required to be purchased in 2007 is now required to be purchased in 2008, less purchases made in 2006 and 2007. As long as the Company continues to meet minimum purchase requirements, the supply and development agreement will automatically renew annually under its terms until the expiration of the last of the patents covering any of the supplied products. The supply and development agreement may be terminated prior to its stated term under specified events, including as a result of a bankruptcy event of either party or an uncured default. In addition, Digital Angel may sell the microchips to third parties if the Company does not take delivery and pay for a minimum number of microchips as specified in the supply and development agreement. Further, the supply and development agreement provides that Digital Angel must, at the Company’s option, furnish and operate a computer database to provide data collection, storage and related services for the Company’s customers for a fee as provided. The Company does not currently utilize this service.

The terms of the original supply and development agreement and each amendment were negotiated by the executive officers of the respective companies and approved by the independent members of each company’s board of directors.

Digital Angel relies solely on a production agreement with RME, a subsidiary of Raytheon Company for the manufacture of its human-implantable microchip products. RME utilizes Digital Angel’s equipment in the production of the microchips. Digital Angel entered into a new production agreement with RME related to the manufacture and distribution of glass-encapsulated syringe-implantable transponders, including the human-implantable microchip products sold by the Company expiring on June 30, 2010. The technology underlying these systems is covered, in part, by U. S. Patent No. 5,211,129, “Syringe-Implantable Identification Transponders,” which the Company refers to as the ‘129 patent. In 1994, Destron/IDI, Inc., a predecessor company to Digital Angel, granted a co-exclusive license under this patent, other than for certain specified fields of use related to Digital Angel’s Animal Applications segment, which were retained by the predecessor company, to Hughes Aircraft Company, or Hughes, and its then wholly owned subsidiary, Hughes Identification Devices, Inc., or HID. The specified fields of use retained by the predecessor company do not include human identification or security applications. The rights licensed to Hughes and HID were freely assignable, and we do not know which party or parties currently have these rights or whether these rights have been assigned, conveyed or transferred to any third party.

The Company does not anticipate generating more than nominal revenue from the sale of its human implantable microchips prior to the expiration of the patent in April 2008. Hughes, HID, any of their respective successors in interest, or any party to whom one of the foregoing parties may have assigned its rights under the 1994 license agreement may commence a claim against the Company asserting that the Company is violating its rights. If such a claim is successful, sales of the Company’s human implantable systems could be enjoined, and the Company could be required to cease its efforts to create a market for these systems, until the patent expires in April 2008. In addition, the Company could be required to pay damages, which may be substantial. Regardless of whether any claimant is successful, the Company would face the prospect of the expenditure of funds in litigation, the diversion of management time and resources, damage to its reputation and the potential impairment in the marketability of its systems even after the expiration of the patent, which could harm the Company’s business and negatively affect its prospects. (See Note 9 “Unasserted Claim — Potential Intellectual Property Conflict”).

Digital Angel and the successor to HID have executed a cross-license which includes Digital Angel obtaining a royalty free non-exclusive license to HID’s rights to the implantable human applications of the ‘129 patent, for which it purports certain ownership rights to. Digital Angel has, in turn, sublicensed those rights to VeriChip. (See Note 9 “Unasserted Claim — Potential Intellectual Property Conflict” and Note 11 “Related Party Transactions”).

Legal Services

During 2006, the Company incurred legal fees relating to its initial public offering of $0.8 million to the Company’s legal counsel, Akin Gump Strauss Hauer & Feld LLP, or Akin Gump. Tommy G. Thompson, a partner with Akin Gump, was a member of the Company’s board of directors from July 2005 to March 8, 2007, and, as a result of his directorship services, as of September 30, 2007, holds fully vested options to purchase 55,556 shares of the Company’s common stock.

Pledge Agreement of Applied Digital

On August 24, 2006, Applied Digital pledged 3,611,111 shares of Company common stock it owns to its lender under the terms of a note and stock pledge agreement. In addition, on August 31, 2007, Applied Digital pledged 4,284,445 shares of Company common stock it owns to an affiliate of its lender, under the terms of a note and stock pledge agreement. Each of the notes mature on February 1, 2010.

12. Supplementary Cash Flow Information

In the nine months ended September 30, 2007, the Company made the following payments for income taxes and interest:


	Nine Months Ended
	September 30,
	2007		2006
Income taxes paid	$	253	$	210
Interest paid		72		24


	$	325	$	234

In the nine months ended September 30, 2007 and 2006, the Company had the following non-cash investing and financing activities:


	Nine Months Ended
	September 30,
	2007		2006

Non-cash financing activities:
Offering costs	$	—	$	1,278

13. Exit and Disposal Activity

In November 2006, the Company made the decision to consolidate its healthcare security operations into an existing facility located in Ottawa, Ontario, Canada to eliminate duplicative functions and to improve operating efficiencies. The consolidation entailed the closing of operations in Vancouver, British Columbia. The Company substantially completed the consolidation by March 31, 2007. As a result of the consolidation, for the three and nine months ended September 30, 2007, the Company has recorded charges of nil and $0.3 million, resulting from payroll related charges. Such charges are reflected in the consolidated statement of operations in selling, general and administrative expense and in research and development expenses.

Special Note Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q contains forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that reflect our current estimates, expectations and projections about our future results, performance, prospects and opportunities. Forward-looking statements include, without limitation, statements about our market opportunities, our business and growth strategies, our projected revenue and expense levels, possible future consolidated results of operations, the adequacy of our available cash resources, our financing plans, our competitive position and the effects of competition and the projected growth of the industries in which we operate. This Quarterly Report on Form 10-Q also contains forward-looking statements attributed to third parties relating to their estimates regarding the size of the future market for products and systems such as our products and systems, and the assumptions underlying such estimates. Forward-looking statements include all statements that are not historical facts and can be identified by forward-looking statements such as “may,” “might,” “should,” “could,” “will,” “intends,” “estimates,” “predicts,” “projects,” “potential,” “continue,” “believes,” “anticipates,” “plans,” “expects” and similar expressions. Forward-looking statements are only predictions based on our current expectations and projections, or those of third parties, about future events and involve risks and uncertainties.

Although we believe that the expectations reflected in the forward-looking statements contained in this Quarterly Report on Form 10-Q are based upon reasonable assumptions, no assurance can be given that such expectations will be attained or that any deviations will not be material. In light of these risks, uncertainties and assumptions, the forward-looking statements, events and circumstances discussed in this Quarterly Report on Form 10-Q may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Important factors that could cause our actual results, level of performance or achievements to differ materially from those expressed or forecasted in, or implied by, the forward-looking statements we make in this Quarterly Report on Form 10-Q are discussed under “Item 1A. Risk Factors” and elsewhere in our Annual Report on Form 10-K and include:

•		our ability to successfully implement our business strategy;

•		our expectation that we will incur losses, on a consolidated basis, for the foreseeable future;

•		our ability to fund our operations;

•		borrowings under our existing bank facility are payable on demand and the facility could be terminated at any time without notice;

•		the impact on our success of the relative maturity in the United States, and limited size, of the markets for our infant protection and wander prevention systems and vibration monitoring instruments;

•		the degree of success we have in leveraging our brand reputation, reseller network and end-use customer base for our infant protection and wander prevention systems to gain inroads in the emerging market for asset/staff location and identification systems;

•		the rate and extent of the U.S. healthcare industry’s adoption of radio frequency identification, or RFID, asset/staff location and identification systems;

•		the relative degree of market acceptance of our zonal, or cell identification, active RFID systems compared to competing technologies, such as lower power Ultra Wide Band-based location technologies, 802.11 and Zigbee-based location and wireless networking technologies;

•		our ability to complete our efforts to introduce new vibration monitoring instrumentation products;

•		uncertainty as to whether we will be able to increase our sales of infant protection and wander prevention systems outside of North America;

•		our reliance on third-party dealers to successfully market and sell our products;

•		we may become subject to costly product liability claims and claims that our products infringe the intellectual property rights of others;

•		our ability to comply with current and future regulations relating to our businesses;

•		uncertainty as to whether a market for our VeriMed and Evitrace systems will develop and whether we will be able to generate more than a nominal level of revenue from the sale of these systems;

•		the potential for patent infringement claims to be brought against us asserting that we hold no rights for the use of the implantable microchip technology and that we are violating another party’s intellectual property rights. If such a claim is successful, we could be enjoined from engaging in activities to market the systems that utilize the implantable microchip and be required to pay substantial damages;

•		market acceptance of our VeriMed system, which will depend in large part on the future availability of insurance reimbursement for the VeriMed system microchip implant procedure from government and private insurers, and the timing of such reimbursement, if it, in fact, occurs;

•		a potential disruption to our business, loss of sales and higher expense if we are unable to obtain the implantable microchip used in our VeriMed and Evitrace systems from our sister company Digital Angel and other risks related to our supply agreement with Digital Angel;

•		our ability to provide uninterrupted, secure access to the VeriMed database;

•		conflict of interest risks related to our continued affiliation with Digital Angel and our parent company, Applied Digital; and

•		our ability to establish and maintain proper and effective internal accounting and financial controls.

You should not place undue reliance on any forward-looking statements. In addition, past financial or operating performance is not necessarily a reliable indicator of future performance, and you should not use our historical performance to anticipate future results or future period trends. Except as otherwise required by federal securities laws, we disclaim any obligation or undertaking to disseminate any updates or revisions to any forward-looking statement contained in this Quarterly Report on Form 10-Q to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based. All forward-looking statements attributable to us, or persons acting on our behalf, are expressly qualified in their entirety by the cautionary statements included in this Quarterly Report on Form 10-Q.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the accompanying financial statements and related notes included in Item 1 of this Quarterly Report on the Form 10-Q as well as our 2006 Annual Report on Form 10-K for the year ended December 31, 2006.

We develop, market, and sell radio frequency identification, frequently referred to as RFID, systems used for the identification, location and protection of people and assets in the healthcare market. In early 2007, we realigned our business into three business segments: healthcare security, implantable, and industrial. This change was made to align our financial reporting with our new operational management structure. All segment information in this Quarterly Report on Form10-Q has been reclassified to reflect the segment realignment.

Our healthcare security segment encompasses the development, marketing and sale of our healthcare security and location systems, specifically:

	•		infant protection systems used in hospital maternity wards and birthing centers to prevent infant abduction and mother-baby mismatching;

	•		wander prevention systems used by long-term care facilities to locate and protect their residents; and

	•		asset/staff location and identification systems used by hospitals and other healthcare facilities to identify, locate and protect medical staff, patients, visitors and medical equipment.

The principal offering of our implantable segment is our VeriMed system using the implantable microchip, a FDA cleared human-implantable RFID microchip that is used in patient identification for access to personal health records.

Our industrial segment encompasses the sale of vibration monitoring instruments used by engineering, construction and mining professionals to monitor the effects of human induced vibrations, such as blasting activity. Our industrial segment also encompasses the sale of asset management systems used by industrial companies to manage and track their mobile equipment and tools.

Highlights for our third quarter ended September 30, 2007, included:

	•		We generated $53,000 from our implantable segment, the first revenue from that segment since our initial public offering, primarily from sales of the VeriTrace System; we also launched the Patient First program, a program under which patients receive the VeriMed™ implantable microchip with no up-front cost with a subscription to the VeriMed Patient Registry at a fee of $9.95 per month.

	•		We partnered with Independent Dialysis Foundation (IDF) of Maryland to provide IDF’s 500 patients access to the VeriMed™ implantable microchip over a one-year period.

	•		We officially launched our VeriMed Patient Identification System project with Alzheimer’s Community Care and more than 100 patients and caregivers received the VeriMed™ implantable microchip following the launch.

	•		We entered into a memorandum of understanding with Digital Angel and RECEPTORS LLC, an expert in the field of proteomics and the development of artificial receptors, to develop a prototype renewable glucose sensor to use in conjunction with an implantable bio-sensing RFID microchip to measure glucose levels in the human body.

•

The number of hospitals registered in the VeriMed Patient Identification System network increased by 9.5% from 640 at the end of the second quarter of 2007 to 701 at the end of the third quarter of 2007. The number of protocol-adopted hospitals increased by 26.6% from 158 at the end of the second quarter of 2007 to 200 at the end of the third quarter of 2007.

Results of Operations

The table below sets forth data from our consolidated statements of operations for the three and nine months ended September 30, 2007 and 2006, expressed as a percentage of total revenue. To date, substantially all of our revenue consists of revenue from our healthcare security and industrial businesses, which were acquired in the first half of 2005.

Through September 30, 2007, we have recorded nominal revenue from sales of our VeriMed system. Over time, we expect that sales of our VeriMed system will become a significant part of our revenue, although there can be no assurance that they will.


	Three Months Ended						Nine Months Ended
	September 30,						September 30,
	2007			2006			2007			2006
Product revenue		93.7	%		93.2	%		93.3	%		93.8	%
Service revenue		6.3			6.8			6.7			6.2


Total revenue		100.0	%		100.0	%		100.0	%		100.0	%


Cost of products sold		38.8			41.5			42.4			38.6
Cost of services sold		3.9			3.2			3.8			3.2


Gross profit		57.3			55.3			53.8			58.2

Selling, general and administrative expense		77.0			63.8			71.7			61.8
Research and development		14.4			12.9			14.9			13.3
Other income		0.5			0.3			0.5			0.3
Interest expense		4.9			3.2			4.9			2.5


Loss before provision for income taxes		(39.4	)		(24.9	)		(38.2	)		(19.6	)
Provision for income taxes		1.3			(6.4	)		0.6			(2.7	)


Net loss attributable to common stockholder		(40.7	)%		(18.5	)		(38.8	)%		(17.0	)%

Three Months Ended September 30, 2007 Compared to Three Months Ended September 30, 2006

The table below presents unaudited condensed statement of operations data by segment and in total for the three months ended September 30, 2007 and 2006.


	2007
	Healthcare
	Security		Implantable			Industrial		Corporate			Total
	(in thousands)
Product revenue	$	5,715	$	53		$	1,646	$	—		$	7,414
Service revenue		158		—			344		—			502


Total revenue		5,873		53			1,990		—			7,916

Gross profit		3,360		37			1,139		—			4,536

Selling, general and administrative		1,945		1,467			559		2,121			6,092
Research and development		665		7			468		—			1,140


Total operating expenses		2,610		1,474			1,027		2,121			7,232


Operating (loss) income	$	750	$	(1,437	)	$	112	$	(2,121	)	$	(2,696	)


	2006
	Healthcare
	Security		Implantable			Industrial		Corporate			Total
	(in thousands)
Product revenue	$	4,934	$	14		$	1,406	$	—		$	6,354
Service revenue		147		—			317		—			464


Total revenue		5,081		14			1,723		—			6,818

Gross profit		2,750		3			1,015		—			3,768

Selling, general and administrative		2,133		1,041			589		585			4,348
Research and development		502		—			380		—			882


Total operating expenses		2,632		1,041			969		585			5,230


Operating income (loss)	$	115	$	(1,038	)	$	46	$	(585	)	$	(1,462	)

Revenue

Revenue for the three months ended September 30, 2007 was $7.9 million, an increase of $1.1 million, or 16.2%, compared to the comparable period of the prior year.

Our healthcare security segment’s revenue was $5.9 million for the three months ended September 30, 2007 compared to $5.1 million for the three months ended September 30, 2006. The $0.8 million increase in revenue in our healthcare security segment is primarily attributable to increased sales of infant protection systems reflecting increased sales volumes generated by our key dealers for both new systems and the sale of RFID tags and other consumables to our installed base. Revenue from the sale of our wander prevention products also increased for the three months ended September 30, 2007 compared to the three months ended September 30, 2006.

Our industrial segment’s revenue was $2.0 million for the three months ended September 30, 2007 compared to $1.7 million for the three months ended September 30, 2006. The $0.3 million increase in revenue in our industrial segment reflects continued strong demand in the worldwide construction market for our vibration monitoring systems. The strength or weakness of the worldwide construction market has historically had a significant influence on the sales volumes of our vibration monitoring instruments.

Our implantable segment revenue was $53,000 for the three months ended September 30, 2007 compared to $14,000 for the three months ended September 30, 2006. This increase is attributable to sales of VeriTrace systems to state and local government agencies.

Gross Profit and Gross Profit Margin

Our cost of products consists of component parts, direct labor and finished goods. Component parts and finished goods are purchased from contract manufacturers, including our implantable microchip and scanners used in our VeriMed system, which are purchased as finished goods under the terms of our agreement with Digital Angel Corporation, or Digital Angel. Moreover, included in our cost of products is amortization of intangible assets acquired in the acquisitions of Instantel Corporation and EXI Wireless Inc., during the first half of 2005. Such amortization amounted to $0.5 million and $0.4 million for the three months ended September 30, 2007 and 2006, respectively.

Cost of services consists primarily of third-party installation services in connection with direct sales to healthcare customers. In addition, cost of services sold in our industrial segment consists of servicing our existing systems, principally the calibration services we provide for our vibration monitoring instruments.

Gross profit for the three months ended September 30, 2007 was $4.5 million compared to $3.8 million for the three months ended September 30, 2006. As a percentage of revenue, our gross profit margin was 57.3% and 55.3% for the three months ended September 30, 2007 and 2006, respectively.

Our healthcare security segment’s gross profit was $3.4 million and $2.8 million for the three months ended September 30, 2007 and 2006, respectively. Our healthcare security segment’s gross profit margin increased to 57.2% in the three months ended September 30, 2007 compared to 54.1% in the three months ended September 30, 2006. The increase in gross profit margin is due to improved inventory management as a result of the consolidation of operations from Vancouver to Ottawa.

Our industrial segment’s gross profit for the three months ended September 30, 2007 was $1.1 million compared to $1.0 million for the three months ended September 30, 2006. Our industrial segment’s gross profit margin decreased to 57.2% in the three months ended September 30, 2007 compared to 58.9% in the three months ended September 30, 2006. The decrease in gross profit margin resulted from increased revenues from the sale of tool management products compared to the three months ended September 30, 2006, which have a lower gross margin than our vibration monitoring products.

Selling, General and Administrative Expense

Selling, general and administrative expense consists primarily of compensation for employees in executive, sales, marketing and operational functions, including finance and accounting, and corporate development. Other significant costs include depreciation and amortization, professional fees for accounting and legal services, consulting fees and facilities costs.

Selling, general and administrative expense increased $1.8 million to $6.1 million for the three months ended September 30, 2007 as compared to $4.3 million for the three months ended September 30, 2006. As a percentage of revenue, selling, general and administrative expense was 77.0% and 63.8% for the three months ended September 30, 2007 and 2006, respectively.

During the three months ended September 30, 2007 and 2006, we incurred stock-based compensation expense of $1.3 million and $0.1 million, respectively.

Included in selling, general and administrative expense was $0.1 and $0.2 million of certain general and administrative services provided to us by Applied Digital, including accounting, finance and legal services, insurance, telephone, rent and other miscellaneous items in both the three months ended September 30, 2007 and 2006.

Selling, general and administrative expense included depreciation and amortization expense of approximately $0.5 million for the three months ended September 30, 2007 and 2006.

Our healthcare security segment’s selling, general and administrative expense was $1.9 million in the three months ended September 30, 2007 as compared to $2.1 million in the three months ended September 30, 2006. The decrease of $0.2 million is a result of cost savings from the close of our Vancouver operations, which was completed in the first quarter of 2007. As a percentage of our healthcare security segment’s revenue, selling, general and administrative expense was 33.1% and 42.0% for the three months ended September 30, 2007 and 2006, respectively.

Our industrial segment’s selling, general and administrative expense remained constant at approximately $0.6 million for the three months ended September 30, 2007 and 2006. As a percentage of our industrial segment’s revenue, selling, general and administrative expense was 28.1% and 34.2% for the three months ended September 30, 2007 compared to the three months ended September 30, 2006, respectively. We attribute the decrease in selling, general, and administrative expense as a percentage of our industrial segment’s revenue primarily to revenue growth in our vibration monitoring business and the fixed nature of our general and administrative expenses.

Our implantable segment’s selling, general and administrative expense increased to $1.5 million from $1.0 million for the three months ended September 30, 2007 compared to the three months ended September 30, 2006. The increase was due to our increased sales and marketing expenses associated with the build out of our VeriMed business, primarily through increased sales staff and costs related to our market development efforts.

Our corporate segment’s selling, general and administrative expense increased from $0.6 million to $2.1 million in three months ended September 30, 2007 compared to the three months ended September 30, 2006. This increase in selling, general and administrative expense during the three months ended September 30, 2007 compared to the three months ended September 30, 2006 was due primarily to non-cash equity based compensation of $1.3 million and the costs of being a public entity.

Research and Development

Research and development expense was $1.1 million for the three months ended September 30, 2007 compared to $0.9 million for the three months ended September 30, 2006. As a percentage of revenue, research and development expense was 14.4% and 12.9% for the three months ended September 30, 2007 and 2006, respectively.

Our healthcare security segment’s research and development expense increased to $0.7 million for the three months ended September 30, 2007 from approximately $0.5 million for the three months ended September 30, 2006. This increase is attributable to higher Canadian dollar denominated compensation costs related to changes in the foreign exchange rate.

Our industrial segment’s research and development expense was approximately $0.5 million for the three months ended September 30, 2007 as compared to $0.4 in the three months ended September 30, 2006.

Interest Expense

Interest expense was $0.4 million and $0.2 million for the three months ended September 30, 2007 and 2006, respectively. The increase in interest expense was due to the increased amount owed and increased interest rate under our loan agreement with Applied Digital, and our increased borrowings under our revolving credit facility with the Royal Bank of Canada. We used a portion of the proceeds from our initial public offering to repay $3.5 million of outstanding indebtedness owed to Applied Digital at the closing of our initial public offering. During the three months ended September 30, 2007 and 2006, the interest rate under our loan agreement with Applied Digital was 12% and 7% per annum, respectively.

Nine Months Ended September 30, 2007 Compared to Nine Months Ended September 30, 2006

The table below presents statement of operations data by segment and in total for the nine months ended September 30, 2007 and 2006.


	2007
	Healthcare
	Security		Implantable			Industrial		Corporate			Total
	(in thousands)
Product revenue	$	16,622	$	54		$	5,233	$	—		$	21,909
Service revenue		424		—			1,146		—			1,570


Total revenue		17,046		54			6,379		—			23,479

Gross profit		9,126		38			3,465		—			12,629

Selling, general and administrative		5,850		3,855			1,817		5,311			16,833
Research and development		2,289		105			1,109		—			3,503


Total operating expenses		8,139		3,960			2,926		5,311			20,336


Operating (loss) income	$	987	$	(3,922	)	$	539	$	(5,311	)	$	(7,707	)


	2006
	Healthcare
	Security		Implantable			Industrial		Corporate			Total
	(in thousands)
Product revenue	$	14,683	$	114		$	4,277	$	—		$	19,074
Service revenue		282		—			988		—			1,270


Total revenue		14,965		114			5,265		—			20,344

Gross profit		8,618		49			3,183		—			11,850

Selling, general and administrative		6,422		2,706			1,582		1,870			12,580
Research and development		1,807		—			893		—			2,700


Total operating expenses		8,229		2,706			2,475		1,870			15,280


Operating income (loss)	$	389	$	(2,657	)	$	708	$	(1,870	)	$	(3,430	)

Revenue

Revenue for the nine months ended September 30, 2007 was $23.5 million, an increase of $3.1 million, or 15.4%, compared to the comparable period of the prior year.

Our healthcare security segment’s revenue was $17.0 million for the nine months ended September 30, 2007 compared to $15.0 million for the nine months ended September 30, 2006. The $2.0 million increase in revenue in our healthcare security segment is primarily attributable to increased sales of infant protection systems reflecting increased sales volumes generated by our key dealers for both new systems and the sale of RFID tags and other consumables to our installed base. Revenue from the sale of our wander prevention products also increased for the nine months ended September 30, 2007 compared to the nine months ended September 30, 2006.

Our industrial segment’s revenue was $6.4 million for the nine months ended September 30, 2007 compared to $5.3 million for the nine months ended September 30, 2006. The $1.1 million increase in revenue in our industrial segment reflects continued strong demand in the worldwide construction market for our vibration monitoring systems. The strength or weakness of the worldwide construction market has historically had a significant influence on the sales volumes of our vibration monitoring instruments.

Our implantable segment’s revenue was $54,000 for the nine months ended September 30, 2007 compared to $0.1 million for the nine months ended September 30, 2006. This decrease is attributable to the sale of access security systems to several international distributors in the first three months of 2006 prior to the shift in our sales and marketing efforts to the build out of our VeriMed business.

Gross Profit and Gross Profit Margin

Our cost of products consists of component parts, direct labor and finished goods. Component parts and finished goods are purchased from contract manufacturers, including our implantable microchip and scanners used in our VeriMed system, which are purchased as finished goods under the terms of our agreement with Digital Angel. Moreover, included in our cost of products is amortization of intangible assets acquired in the acquisitions of Instantel Corporation and EXI Wireless Inc., during the first half of 2005. Such amortization amounted to $1.4 million for the nine months ended September 30, 2007 and 2006.

Gross profit was $12.6 million and $11.9 million for the nine months ended September 30, 2007 and 2006, respectively. As a percentage of revenue, our gross profit margin was 53.8% and 58.2% for the nine months ended September 30, 2007 and 2006, respectively.

Our healthcare security segment’s gross profit for the nine months ended September 30, 2007 was $9.1 million compared to $8.6 million for the nine months ended September 30, 2006. Comparing the same nine month periods, gross profit margin decreased to 53.5% in the nine months ended September 30, 2007 from 57.6% in the nine months ended September 30, 2006. The decline in gross profit margin is the result of increased warranty costs related to our former Vancouver operations in the first half of 2007. Our improved inventory management processes in our Ottawa facility have resulted in a reduction of these costs and as a result in the three months ended September 30, 2007 gross profit margin increased to 57.2% compared to 54.1% in the three months ended September 30, 2006.

Our industrial segment’s gross profit for the nine months ended September 30, 2007 was $3.5 million compared to $3.2 million for the nine months ended September 30, 2006. Our industrial segment’s gross profit margin decreased to 54.3% in the nine months ended September 30, 2007 compared to 60.5% in the nine months ended September 30, 2006. The decline in gross profit margin resulted from increased inventory reserves for slower moving inventory and due to increased revenues from tool management products compared to the nine months ended September 30, 2006, which have a lower gross margin that our vibration monitoring products.

Our implantable segment’s gross profit decreased from $49,000 for the nine months ended September 30, 2006 to $38,000 for the nine months ended September 30, 2007. The $11,000 decrease resulted from the decrease in revenue from access security systems sold in early 2006.

Selling, General and Administrative Expense

Selling, general and administrative expense increased $4.2 million to $16.8 million for the nine months ended September 30, 2007 as compared to $12.6 million for the nine months ended September 30, 2006. As a percentage of revenue, selling, general and administrative expense was 71.7% and 61.8% for the nine months ended September 30, 2007 and 2006, respectively. For the remainder of 2007, we expect the increased year over year selling, general and administrative expense to continue as a result of the build out of our VeriMed business, the cost resulting from the issuance of equity based compensation, and the cost related to becoming a public entity.

During the nine months ended September 30, 2007 and 2006, we incurred stock-based compensation expense of $2.6 million and $0.1 million, respectively.

Included in selling, general and administrative expense was $0.4 million of certain general and administrative services provided to us by Applied Digital, including accounting, finance and legal services, insurance, telephone, rent and other miscellaneous items in both the nine months ended September 30, 2007 and 2006.

Selling, general and administrative expense included depreciation and amortization expense of approximately $1.5 million and $0.5 million for the nine months ended September 30, 2007 and 2006, respectively.

Our healthcare security segment’s selling, general and administrative expense was $5.9 million and $6.4 million in the nine months ended September 30, 2007 and 2006, respectively. As a percentage of our healthcare security segment’s revenue, selling, general and administrative expense was 34.3% and 42.9% for the nine months ended September 30, 2007 and 2006, respectively. The decrease of $0.5 million is a result of cost savings from the closing of our Vancouver operations in the first quarter of 2007. We expect to continue to realize cost savings year over year from the closing of our Vancouver operations.

Our industrial segment’s selling, general and administrative expense increased approximately $0.2 million to $1.8 million for the nine months ended September 30, 2007 compared to the nine months ended September 30, 2006. As a percentage of our industrial segment’s revenue, selling, general and administrative expense was 28.5% and 30.0% for the nine months ended September 30, 2007 and 2006, respectively. We attribute the decrease in selling, general, and administrative expense as a percentage of segment revenue primarily to revenue growth in our vibration monitoring business and the fixed nature of our general and administrative expenses.

Our implantable segment’s selling, general and administrative expense increased $1.2 million to $3.9 million for the nine months ended September 30, 2007 compared to the nine months ended September 30, 2006. The increase was due to our increased sales and marketing expenses associated with the build out of our VeriMed business, primarily through increased sales staff and costs related to our market development efforts.

Our corporate segment’s selling, general and administrative expense increased $3.4 million to $5.3 million in nine months ended September 30, 2007 compared to the nine months ended September 30, 2006. This increase was due primarily to the additional costs resulting from non-cash equity based compensation of $2.6 million and increased costs related to being a public entity during the nine months ended September 30, 2007. We expect the increased year over year selling, general and administrative expense to continue as a result of the costs of equity based compensation and costs related to being a public entity.

Research and Development

Our research and development expense consists primarily of payroll costs for engineering personnel and costs associated with various projects, including testing, developing prototypes and related expenses. Research and development expense was $3.5 million for the nine months ended September 30, 2007 compared to $2.7 million for the nine months ended September 30, 2006. As a percentage of revenue, research and development expense was 14.9% and 13.3% for the nine months ended September 30, 2007 and 2006, respectively.

Our healthcare security segment’s research and development expense increased $0.5 million to approximately $2.3 million for the nine months ended September 30, 2007 compared to the nine months ended September 30, 2006. The increase in our healthcare security segment’s research and development expense was due to the costs of duplicative staffing during the period of closing our Vancouver facility in early 2007.

Our industrial segment’s research and development expense was approximately $1.1 million and $0.9 million for the nine months ended September 30, 2007 and 2006, respectively.

Our implantable segment’s research and development expense was approximately $0.1 million and nil for the nine months ended September 30, 2007 and 2006, respectively.

Interest Expense

Interest expense was $1.1 million and $0.5 million for the nine months ended September 30, 2007 and 2006, respectively. The increase in interest expense was due to the increased amount owed and increased interest rate under our loan agreement with Applied Digital, and our increased borrowings under our revolving credit facility with the Royal Bank of Canada. We used a portion of the proceeds from our initial public offering to repay $3.5 million of outstanding indebtedness owed to Applied Digital at the closing of our initial public offering. During the nine months ended September 30, 2007 and 2006, the interest rate under our loan agreement with Applied Digital was 12% and 7% per annum, respectively.

Liquidity and Capital Resources

As of September 30, 2007, cash totaled $9.7 million compared to cash of approximately $1.0 million at December 31, 2006.

Cash Flows Used in Operating Activities

Net cash used in operating activities totaled $5.0 million and $1.8 million during the nine months ended September 30, 2007 and 2006, respectively. For each of the periods presented, cash was used primarily to fund operating losses, accounts receivable, and payments of accounts payable and accrued expenses.

Since our acquisitions of our healthcare security and industrial businesses in the first half of 2005, we have generated operating cash flows from such operations that have partially funded our efforts to create a market for our VeriMed system. We expect to continue to generate significant net cash operating outflows for the foreseeable future in our VeriMed business as a result of our continuing investment in marketing and sales efforts related to our VeriMed business. We expect that these net cash operating outflows will continue to be funded through cash flows generated by our Healthcare Security and Industrial operations, as well as from the net proceeds of our initial public offering. As a result, we expect that our consolidated statements of cash flows will reflect significant cash flows used in operating activities for at least the next 12-24 months.

The components of our VeriMed system (i.e., scanners, insertion kits and the implantable microchips) are purchased as finished goods under the terms of our agreement with Digital Angel. The agreement imposes minimum purchase requirements as follows: $0 million in 2007; $0.9 million in 2008, net of $0.4 million of purchases in 2006 and less purchases made in 2007; $1.8 million in 2009; $2.5 million in 2010; $3.8 million in 2011; and $3.8 million in each year thereafter, subject to the parties reaching agreement on a different amount. Under the terms of the agreement, Digital Angel may not supply human implantable microchips to other parties if we meet the minimum purchase requirements. If sales of the implantable microchip do not materialize or do not reach the level of the applicable minimum purchase requirement in any year, we intend to satisfy the minimum purchase requirements nonetheless. In such event, our inventory of implantable microchips will increase. We believe that we will have sufficient liquidity to meet the minimum purchase requirements under the agreement for the next few years.

Cash Flows from Investing Activities

Investing activities used cash of $0.4 million and $0.6 million during the nine months ended September 30, 2007 and 2006, respectively, which was used to purchase equipment.

Cash Flows from Financing Activities

Financing activities provided cash of $14.2 million and $1.9 million during the nine months ended September 30, 2007 and 2006, respectively. In the nine months ended September 30, 2007 and 2006, cash of $0.6 million and $1.0 million was provided from net borrowings under our credit agreement with the Royal Bank of Canada and cash of $3.5 million was paid to Applied Digital as principle payment on our Note Payable in the nine months ended September 30, 2007. During the nine months ended September 30, 2007 and 2006, borrowing of $1.3 million and $2.1 million were made from Applied Digital. During the nine months ended September 30, 2007, cash of $15.5 million was provided from our initial public offering, net of underwriting fees and offering costs.

Credit Facilities

Prior to the date of our initial public offering, which was consummated on February 14, 2007, we financed a significant portion of our operations and investing activities primarily through funds that Applied Digital provided. As of September 30, 2007, we were indebted to Applied Digital in the amount of $12.5 million.

Through October 5, 2006, our loan with Applied Digital bore interest at the prevailing prime rate of interest as published by The Wall Street Journal , which as of September 30, 2006 was 8.25% per annum. On October 6, 2006, we entered into an amendment to the loan agreement which increased the principal amount available thereunder to $13.0 million and we borrowed an additional $2.0 million under the agreement to make the second purchase price payment with respect to our acquisition of Instantel Inc. In connection with that amendment, the interest rate was also changed to a fixed rate of 12% per annum. That amendment further provided that the loan matured on July 1, 2008, but could be extended at the option of Applied Digital through December 27, 2010.

On January 19, 2007, February 8, 2007 and February 13, 2007, we entered into further amendments to the loan documents which increased the maximum principal amount of indebtedness that we may incur to $14.5 million. A portion of this increase was used to cover approximately $0.7 million of intercompany advances made to us by Applied Digital during the first week of January 2007. Upon the consummation of our initial public offering in February 2007, the loan ceased to be a revolving line of credit, and we have no ability to incur additional indebtedness under the loan documents. The interest continues to accrue on the outstanding indebtedness at a rate of 12% per annum. On February 14, 2007, the closing date of our initial public offering, we were indebted to Applied Digital in the amount of $15.1 million, including $1.0 million of accrued interest and, in accordance with the terms of the loan agreement as most recently amended on February 13, 2007, we used $3.5 million of the net proceeds of our initial public offering to repay a portion

of our indebtedness to Applied Digital upon consummation of our initial public offering. We are not obligated to repay an additional amount of our indebtedness until January 1, 2008. Effective with the payment of the $3.5 million, all interest which accrues on the loan as of the last day of each month, commencing with February 2007, is added to the principal amount. Commencing January 1, 2008 through January 1, 2010, we are obligated to repay $300,000 on the first day of each month. A final balloon payment equal to the outstanding principal amount then due under the loan plus all accrued and unpaid interest will be due and payable on February 1, 2010. We amended the repayment terms of the loan to allow us to retain a greater portion of the net proceeds of our initial public offering for use in our business, thereby improving our liquidity for at least the next 12 to 18 months.

Our subsidiary, VeriChip Holdings Inc., or VHI, has entered into a credit facility dated March 15, 2006 with the Royal Bank of Canada, or RBC, providing for up to CDN$1.5 million, or approximately $1.5 million based on the exchange rate as of September 30, 2007, of revolving credit loans, provided that outstanding borrowings under the facility may not exceed at any time an amount determined by reference to eligible accounts receivable plus eligible inventory, in each case as defined in the agreement, of VHI, or CDN$3.8 million at September 30, 2007. At September 30, 2007, $1.5 million was outstanding under the facility. The facility is not a committed facility as it provides that loans are made available to VHI at the sole discretion of RBC and that RBC may cancel or restrict the availability or any unutilized portion thereof at any time or from time to time. Borrowings may be made in either Canadian or U.S. dollars, are repayable on demand, as a result of which outstanding borrowings under the facility are reflected as current liabilities in our consolidated financial statements, and bear interest at a floating rate per annum equal to the Canadian or U.S. dollar prime rate, as applicable, announced by RBC from time to time, plus in each case 1%. The facility also provides for letters of credit and letters of guarantee denominated in Canadian dollars. Borrowings, letters of credit and letters of guarantee under the facility are secured by all of the assets of VHI and its subsidiary, and is guaranteed by VHI’s subsidiary in the amount of CDN$2.0 million. The loan agreements contain customary representations and warranties and events of default for loan arrangements of this type. In addition, the loan agreements contain customary covenants restricting VHI’s ability to, among other things, merge or enter into business combinations, create liens, or sell or otherwise transfer assets. The foregoing is a summary of the material terms of the credit facility and related agreements, and is qualified in its entirety by reference to the terms and provisions of those agreements.

Financial Condition

As of September 30, 2007, we had working capital of approximately $10.1 million and an accumulated deficit of $26.2 million compared to a working capital of approximately $0.8 million and an accumulated deficit of approximately $17.0 million as of December 31, 2006. The increase in working capital was primarily due to proceeds from our initial public offering completed on February 14, 2007, net of offering costs and underwriter fees, on February 14, 2007.

We believe that with the remaining net proceeds of our initial public offering, together with the cash we have on hand, our expected borrowing capacity under current or new bank facilities and operating cash flows we expect to generate from our Healthcare Security and Industrial segments, we will have sufficient funds available to cover our cash requirements, including capital expenditures, debt service requirements and the minimum purchase obligations under our supply agreement with Digital Angel, through 2008. However, a decrease in operating cash flows from our healthcare security and industrial businesses, or our inability to enter into a larger, committed bank credit facility, or failure to control or, as necessary, reduce costs related to our continuing investment in our VeriMed business, would have a material adverse effect on our planned business operations, financial condition, results of operations and liquidity.

Impact of Recently Issued Accounting Standards

In February 2007, FASB issued SFAS No. 159, The Fair Value Option for Financial Assets and Financial Liabilities (“FAS 159”), including an amendment of FAS 115. This statement provides companies with an option to report selected financial assets and liabilities at fair value. This statement is effective for fiscal years beginning after November 15, 2007 with early adoption permitted. We are currently assessing the impact that the adoption of FAS 159 could have on results of operations or financial position, if any.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

We presently do not use any derivative financial instruments to hedge our exposure to adverse fluctuations in interest rates, foreign exchange rates, fluctuations in commodity prices or other market risks, nor do we invest in speculative financial instruments. Our line of credit with the Royal Bank of Canada bears interest at the Bank of Canada prime rate plus 1%. Our interest income is sensitive to changes in the general level of U.S. interest rates, particularly since our investments are short-term.

Due to the nature of our short-term investments, we have concluded that there is no material market risk exposure and, therefore, no quantitative tabular disclosures are required. Due to the minimal amounts of foreign currency exchange gains and losses and translation adjustments during the nine months ended September 30, 2007, a sensitivity analysis of fluctuations in foreign currency exchange rates is not required. During the nine months ended September 30, 2007, we incurred $0.4 million in foreign exchange loss primarily from the fluctuation of Canadian dollar exchange related RBC credit facility and other Canadian denominated liabilities.

The table below presents the principal amount, including accrued interest, and weighted-average interest rate for our debt portfolio:


	September
	30, 2007
	(dollars in thousands)
Loan due Applied Digital	$	12,535
Credit agreement with Royal Bank of Canada	$	1,465
Weighted-average interest rate for the nine months ended September 30, 2007		11.6	%

Based upon the average variable rate debt outstanding during the nine months ended September 30, 2007, a 1% change in our variable interest rates would have a de minimis affect on our loss before income taxes.

The estimated fair value of our indebtedness to Applied Digital is not reasonably determinable due to the related party nature of the instrument.

Item 4. Controls and Procedures.

Disclosure Controls and Procedures

Evaluation of Disclosure Controls . We evaluated the effectiveness of the design and operation of our “disclosure controls and procedures” as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) as of September 30, 2007. This evaluation (the “disclosure controls evaluation”) was done under the supervision and with the participation of management, including our chief executive officer (“CEO”) and chief financial officer (“CFO”). Rules adopted by the SEC require that in this section of our Quarterly Report on Form 10-Q we present the conclusions of the CEO and CFO about the effectiveness of our disclosure controls and procedures as of September 30, 2007 based on the disclosure controls evaluation.

Objective of Controls. Our disclosure controls and procedures are designed so that information required to be disclosed in our reports filed under the Exchange Act, such as this Quarterly Report on Form 10-Q, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Our disclosure controls and procedures are also intended to ensure that such information is accumulated and communicated to our management, including the CEO and CFO, as appropriate to allow timely decisions regarding required disclosure. There are inherent limitations to the effectiveness of any system of disclosure controls and procedures, including the possibility of human error and the circumvention or overriding of the controls and procedures. Accordingly, even effective disclosure controls and procedures can only provide reasonable assurance of achieving their control objectives, and management necessarily is required to use its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures.

Conclusion . Based upon the disclosure controls evaluation, our CEO and CFO have concluded that, as of September 30, 2007, our disclosure controls and procedures were effective to provide reasonable assurance that the foregoing objectives are achieved.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of Rule 13a-15 under the Exchange Act that occurred during the quarter ended September 30, 2007 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II — OTHER INFORMATION

Item 1. Legal Proceedings.

The Company is a party to various legal actions, as either plaintiff or defendant, arising in the ordinary course of business, none of which is expected to have a material adverse effect on our business, financial condition or results of operations.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.


ISSUER PURCHASES OF EQUITY SECURITIES ⁽¹⁾
					(c) Total Number of		(d) Approximate Dollar
			(b) Average		Shares (or Units)		Value of Shares (or
	(a) Total Number		Price Paid per		Purchased as Part of		Units) that May Yet Be
	of Shares (or		Share (or		Publicly Announced		Purchased Under the
Period	Units) Purchased ⁽²⁾		Unit) ⁽³⁾		Plans or Programs		Plans or Programs
9/20/2007 - 9/30/2007		18,000	$	4.38		18,000	$	1,420,000
10/1/2007 - 10/31/2007		163,199	$	4.18		163,199	$	740,000
Total		181,199	$	4.20		181,199	$	740,000


(1)		The Company’s stock repurchase program was announced on September 20, 2007. The Company’s board of directors unanimously authorized the repurchase of up to $1.5 million of Company common stock over a four month period.

(2)		All shares were purchased through the Company’s publicly announced stock repurchase plan. The purchases were made in open market transactions.

(3)		The average price paid per share includes commissions paid to effect the transactions.

Item 6. Exhibits.


Exhibit
Number		Description
2.1		Acquisition Agreement dated as of January 25, 2005 between Applied Digital Solutions, Inc. and EXI Wireless Inc. (1)
2.2		Amendment to Acquisition Agreement dated as of March 11, 2005 between Applied Digital Solutions, Inc. and EXI Wireless Systems Inc. (1)
2.3		Exchange Agreement dated as of June 9, 2005 between Applied Digital Solutions, Inc. and VeriChip Corporation (1)
2.4		Waiver and Release between Applied Digital Solutions, Inc. and VeriChip Corporation (1)
2.5		Share Purchase Agreement dated as of June 10, 2005 by and among Instantel Inc., Instantel Holding Company s.ár.l., Perceptis, L.P., VeriChip Inc., Applied Digital Solutions, Inc. and VeriChip Corporation (1)
2.6		Letter Agreement dated as of December 21, 2005, by and among VeriChip Corporation, VeriChip Inc., and Applied Digital Solutions, Inc. (1)
2.7		Registration Rights Agreement dated as of June 10, 2005 between VeriChip Corporation and Perceptis, L.P. (1)
3.1		Second Amended and Restated Certificate of Incorporation of VeriChip Corporation filed with the Secretary of State of Delaware on December 18, 2006 (1)
3.2		Amended and Restated By-laws of VeriChip Corporation adopted as of December 12, 2005 (1)
4.1		Warrant Agreement dated as of August 21, 2002 between VeriChip Corporation and IBM Credit Corporation (1)
4.2		Form of Specimen Common Stock Certificate (1)
4.3		Form of Warrant to Purchase Common Stock of VeriChip Corporation (1)
10.1*		Form of Stock Award Agreement
10.2		Consulting Agreement dated as of August 8, 2007, between VeriChip Corporation and Randolph K. Geissler(2)
10.3		Registration Rights Agreement dated as of August 31, 2007, between VeriChip Corporation and Kallina Corporation(3)
31.1*		Certification by Scott R. Silverman, Chief Executive Officer, pursuant to Exchange Act Rules 13A-14(a) and 15d-14(a)
31.2*		Certification by William J. Caragol, Chief Financial Officer, pursuant to Exchange Act Rules 13A-14(a) and 15d-14(a)
32.1*		Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002


*		Filed herewith.

(1)		Incorporated by reference to the Registration Statement on Form S-1 previously filed by VeriChip Corporation (Registration No. 333-130754).

(2)		Incorporated by reference to the Quarterly Report on Form 10-Q previously filed by VeriChip Corporation on August 8, 2007.

(3)		Incorporated by reference to the Current Report on Form 8-K previously filed by VeriChip Corporation on September 7, 2007.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


	VERICHIP CORPORATION (Registrant)
Date: November 8, 2007	By:	/s/ William J. Caragol
		William J. Caragol
		President, Chief Financial Officer, Treasurer and Secretary

Exhibit Index


Exhibit
Number		Description
10.1		Form of Stock Award Agreement
31.1		Certification by Scott R. Silverman, Chief Executive Officer, pursuant to Exchange Act Rules 13A-14(a) and 15d-14(a)
31.2		Certification by William J. Caragol, Chief Financial Officer, pursuant to Exchange Act Rules 13A-14(a) and 15d-14(a)
32.1		Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002